Contact: Jeff Ezell
BD Public Relations
Franklin Lakes, NJ (November 21, 2008) --
BD announced today that it has increased production capacity for BD SafetyGlide™ Needles and other safety-engineered injection devices to meet U.S. healthcare market needs. This increase is in response to the impending withdrawal of certain Covidien Magellan™ Safety Hypodermic Needles, which have been found to infringe a BD patent. By Court order, Covidien must cease manufacturing and selling these infringing products by December 17, 2008.
For nearly 20 years, BD has been a pioneer and leader in developing high-quality, easy-to-use injection devices designed to protect healthcare workers from needlestick injuries and exposure to bloodborne pathogens. The Company offers one of the most complete lines of advanced safety-engineered products in the industry, which includes award-winning BD SafetyGlide Needles. This breakthrough innovation, which has become the safety needle of choice among clinicians worldwide, uses patented BD Activation-Assist™ technology to provide assurance that the needle is covered.
Hospital procurement officials and clinicians with questions are encouraged to contact BD at 1-888-237-2762. BD’s trained sales experts are ready to advise and assist customers through the conversion process.
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.